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Abstract
Human papillomavirus 8 (HPV8) is a representative of Epidermodysplasia verruciformis (EV)-associated viruses. Transient assays in the
human skin keratinocyte cell line RTS3b have shown that its replication depends in trans on expression of the viral proteins E1 and E2,
similarly to other HPVs. Using deletion mutants and cloned subfragments of the noncoding region (NCR) of HPV8 we identified a 65-bp
sequence in the 3 part of the NCR to be necessary and sufficient to support replication in cis. The origin of replication (ori) of HPV8 is
composed of the sequence motifs “CCAAC” (nt 57–73) and M29 (nt 84–112), which are highly conserved among the majority of EV HPVs.
Analysis of M29 revealed an unconventional binding site of the E2 protein and an overlapping DNA recognition site of the tumor suppressor
protein p53. Both these factors competitively bind to M29. In transient replication assays p53 acted as a potent inhibitor of ori activity, most
probably in a DNA-binding-dependent fashion. The minimal ori sequences are also functionally critical for the E6 oncogene promoter P175.
In contrast to its effect on replication, p53 stimulated promoter activity depending on its interaction with M29. Our observations suggest
that p53 is involved in controlling the balance between DNA replication and gene expression of HPV8.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Human papillomaviruses (HPVs) are ubiquitously occur-
ring small, unenveloped, double-stranded DNA viruses re-
sponsible for induction of a broad spectrum of tumors of the
skin and mucosa in man. More than 100 HPV types have
been characterized and many additional types are suspected
to exist (Howley and Lowy, 2001). The most characteristic
feature of HPVs is their specific tropism for stratified epi-
thelia. HPV particles gain access to proliferating basal ker-
atinocytes, probably through microwounds, and can there-
after establish a persistent infection of the epithelium. The
complete virus life cycle is strictly bound to differentiation
of the cells within the stratified epithelium. This phenome-
non results in a programmed expression of the early and late
viral proteins.
The synthesis of viral DNA can take place in form of
either a maintenance replication, characterized by establish-
ment of episomal viral genomes at low copy numbers in the
basal stratum of the epithelium, or as extensive, vegetative
DNA replication in the differentiating keratinocytes (Chow
and Broker, 1994). There is evidence that these separate
phases employ two different molecular replication mecha-
nisms: bidirectional replication via -DNA structures and
the rolling circle modus, respectively (Flores and Lambert,
1997; Yang and Botchan, 1990).
Due to the lack of a generally applicable in vivo DNA
replication system for HPVs, most of the data concerning
the involved mechanisms originate thus far from transient
replication assays with immortalized cells (Ustav and Sten-
lund, 1991). According to these, replication of the viral
DNA is initiated at the origin of DNA replication (ori)
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element within the noncoding region (NCR) of the virus and
depends in trans primarily on its physical interactions with
the two viral proteins E1 and E2 (Chow and Broker, 1994;
Lambert, 1991; Stenlund, 1996). E1 is a sequence-specific
DNA-binding, replication-initiating factor with properties
of an ATPase, helicase, and DNA unwinding protein (Sed-
man and Stenlund, 1998). The postulated role of E2 is the
recruitment of E1 to the ori locus via its ability to form
complexes with E1 and due to high-affinity E2-binding sites
located within all known HPV ori elements (Berg and Sten-
lund, 1997; Bonne-Andrea et al., 1997). Both these factors
collaborate in an assembly of a functional preinitiation com-
plex with host proteins, which constitute the actual replica-
tion machinery.
Data on the structure of ori elements in papillomaviruses
and on factors involved in their activity are to date almost
exclusively limited to bovine papillomavirus 1 (BPV 1) and
the mucosa-specific types HPV11 (Lu et al., 1993) and
HPV18 (Lee et al., 1997; Sverdrup and Khan, 1995). In
contrast little attention has been paid in this regard to cuta-
neous HPVs except for HPV1 (Gopalakrishnan and Khan,
1994). Epidemiological studies of the last years have shown
an overwhelming majority of skin-specific HPVs to belong
to the group of so-called EV HPVs. The prototypes of these
viruses have been isolated from lesions of patients suffering
from the rare skin cancer syndrome Epidermodysplasia ver-
ruciformis (EV). There are strong indications that several of
these HPV types are causally involved in the development
of skin neoplasia. This is supported by the fact that in
contrast to the plurality of EV-associated HPVs in benign
tumors, only a few virus types, predominantly HPV5 and
HPV8, could be detected in nearly all EV cancers and that
their E6 proteins possess cell-transforming potential in vitro
(Iftner et al., 1988). Whereas the oncoprotein E6 of HPV16
and HPV18 interacts with and leads to degradation of the
tumor suppressor protein p53 (Scheffner et al., 1990), no
such property could be observed for the corresponding pro-
teins of the EV viruses (Steger and Pfister, 1992).
Based on DNA sequence data, EV HPVs form a separate
group of phylogenetically related papillomaviruses (Myers
et al., 1997). EV-HPVs are distinguished by a peculiar
organization of their NCRs, which among other regulatory
sequences also contain the ori element. The NCRs of all
EV-associated HPVs are relatively shorter and the majority
display a pattern of characteristic, highly conserved se-
quence motifs, not recognizable in other papillomaviruses
(Ensser and Pfister, 1990; Fuchs and Pfister, 1997; Krubke
et al., 1987). All these elements are heavily involved in
interactions with cellular proteins, some of which could be
proven to play an important role in the activity of the viral
promoters (May et al., 1991, 1994; Pajunk et al., 1997).
In this report we describe identification and characteriza-
tion of the ori sequence of HPV8, a typical representative of
the oncogenic EV HPVs, and discuss the importance of
interactions with p53 in the regulation of viral replication
and gene expression.
Results
Mapping of the minimal ori element of HPV8
We initially confirmed that similarly to other papilloma-
viruses studied in this regard, the ability of HPV8 DNA to
replicate transiently in vitro depended in cis on sequences
within the viral NCR and in trans on the expression of the
viral E1 and E2 proteins. To this end we cotransfected the
E1 and E2 expression vectors pCE1 and pCE2 either alone
or together with the replication test plasmid pNCR8-CAT,
which contains the NCR region (nt 7077–558) of HPV8
(Stubenrauch et al., 1992). As shown in Fig. 1, transfection
of this test plasmid alone or with either of the expression
vectors did not give rise to detectable replication, whereas
transfection of all three DNAs together resulted in replica-
tion. Analysis of 5-deletion mutants of the HPV8 NCR,
pNCR8CAT-7642, -7535, -7422, and -112 (Stubenrauch et
al., 1992) for their replicational activity revealed that the
ori-containing region resides between positions 7642 and
112 within the E6 ORF proximal part of the NCR (data not
shown). In contrast, no replication could be observed for
plasmid pNCR8-5-Luc, which contained a part of the L1
ORF and the L1 proximal NCR sequences (nt 7077–9). The
ori fragment of the HPV8 genome thus defined displays four
sequence motifs, highly conserved among the majority of
known EV-associated and genetically related HPVs. These
include two binding sites of the viral E2 protein (P3 and P4)
as well as the two unique motifs “CCAAC” (nt 57–73) and
M29 (nt 84–112) originally defined as conserved elements
by sequence alignment of the HPV8, 19, and 25 NCR
regions (Krubke et al., 1987). In order to dissect the HPV8
ori region functionally a series of subfragments has been
generated by PCR (Fig. 2A), cloned into the vector pUC8
(plasmids p81–p88), and subjected to transient replication
tests. As shown in Fig. 2B the 65-bp NCR fragment in the
test plasmid p88, encompassing the CCAAC and M29 mo-
tifs (nt 53–117), proved to be necessary and sufficient in cis
to drive DNA replication of the test plasmids used and can
therefore be regarded as the minimal ori element of HPV8.
Furthermore, comparison of the test constructs p85 through
p88 clearly shows that both CCAAC and M29 are equally
essential in mediating ori activity.
Fig. 1. HPV8-E1 and -E2 are necessary in trans for DNA replication.
pNCR8-CAT (3.5 g) was transfected either alone or together with 2 g
of either pCE1 or pCE2 expression vector or with 2 g of each expression
vector. Low-molecular-weight DNA was isolated and linearized with
BamHI. Half of each sample was then digested with Dpnl ( or ). The
preparations were finally analyzed by Southern blot hybridization as de-
scribed in the text.
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The minimal ori element of HPV8 contains a
noncanonical E2-binding site
HPV8 NCR and L1 ORF contain five known binding sites
of the viral transcriptional regulator/replication protein E2
(P0–P4; Ensser and Pfister, 1990). To test for functional de-
pendence of the HPV8 ori element on interactions of E2 with
these sites we analyzed in transient replication assays a number
of NCR mutants, disabled in binding of E2 protein to these
target sequences. All mutated constructs tested in this regard
turned out to replicate at rates directly comparable to those of
the wild-type NCR. Surprisingly, this also held true for the
plasmid P01234, which contained all five known E2-binding
sites (E2BS) in a functionally inactive form (data not shown).
Inspection of the minimal ori sequence, however, disclosed a
palindromic motif, 5-ATCGN4CGAT-3, within the M29 el-
ement which overall resembles the general E2 consensus bind-
ing site 5-ACCGN4CGGT-3 (Androphy et al., 1987; Fig.
3A). In order to determine the capacity of E2 to physically
interact with this motif we performed gel retardation tests using
the oligonucleotide M29E2, which spans the sequence in ques-
tion within the M29 element and purified HPV8-E2 protein,
synthesized in a baculovirus expression system. As can be seen
in Fig. 3, M29E2 was able to generate a complex with the E2
protein (Fig. 3B, lane 2), migrating in parallel to the one
formed by the oligonucleotide P2C, which carries a well-
characterized, high-affinity E2-binding site (Fig. 3B, lane 8).
The DNA–E2 complex did not appear when the binding reac-
tion was run in the presence of an excess of the nonlabeled
target oligos (Fig. 3B, lanes 3 and 4). In contrast, however,
both heterologous oligonucleotide SP1 and a mutated form of
M29E2 (M29E2mut) which contains two nucleotide ex-
changes within the conserved left flank of the putative E2-
binding palindrome failed to compete in an interaction of
M29E2 with the E2 protein. Since the latter findings argue for
a sequence-specific DNA–protein interaction it may be as-
sumed that the M29 element contains an aberrant, E2-binding
site. Consequent to the previous nomenclature we denote it
further as P5. To prove that this new E2-binding site is indeed
involved in DNA replication we introduced the two nucleotide
exchanges as described in Fig. 3A into the ori E2-binding site
in the plasmid p88 (p88E2mut). In replication tests we dem-
Fig. 2. Mapping of the HPV8 origin of DNA replication (ori). (A) The NCR subfragments of HPV8 which were cloned into pUC8 (p81–p88) and used in
transient replication assays to map the minimal ori. P3, P4, E2-binding site; CCAAC motif, M29, A/T, conserved sequence elements of EV HPVs, HPV8
nucleotides 57–73, 84–112, 84–112, respectively. (B) Functional mapping of the HPV8 ori. Transient replication analysis of the various plasmids in RTS3b
cells. Low-molecular-weight DNA was isolated and linearized with BamHI. Half of each sample was then digested with Dpnl ( or ). The preparations
were finally analyzed by Southern blot hybridization.
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onstrated that the plasmid p88E2mut was no longer able to
replicate transiently (Fig. 2). This shows the importance of the
cryptic E2 site for ori activity.
Tumor suppressor protein p53 binds to the ori element of
HPV8
In the course of computer-assisted analysis to identify
cellular factors interacting with regulatory sequences within
the ori fragment we became aware that the M29 element and
its immediate 5 vicinity display similarity to a potential
p53-binding site, as defined by El-Deiry et al. (1992). In
comparison to the p53 consensus binding site which con-
sists of two copies of the 10-bp motif 5-PuPuPuC(A/T)(T/
A)GPyPyPy-3, separated by a 0- to 13-bp spacer, the two
decamers of the p53-binding site in HPV8 are separated by
14 bp. The p53-binding site in M29 differs from the con-
sensus sequence in the flanking sequences, where there are
pyrimidine bases in the conserved purin regions. Interest-
ingly, this site overlaps with the newly defined E2-binding
site P5. To verify this observation we tested for direct
interaction of p53 protein with the oligonucleotide M29com
by means of EMSA (Fig. 4B) with in vitro translated p53.
The reactions were performed in the presence of pAb421, an
antibody previously shown to interact with the C-terminus
of p53 and to activate sequence-specific DNA binding
(Hupp et al., 1992). As shown in Fig. 4B a specific complex
between p53 and the M29com oligonucleotide was ob-
served only when the antibody pAb421 was present. Com-
petition experiments revealed that the formation of the p53–
M29com complex was prevented by the presence of excess
unlabeled competitors such as the M29 oligonucleotide or
p53 control oligonucleotide, which contains a consensus
p53-binding site. In contrast, using the heterologous SP1 or
p53-control oligonucleotides the p53–M29 DNA complexes
could still be seen. These data clearly show that the ori
element of HPV8 is involved in direct physical interaction
with the cell cycle regulator protein p53.
Fig. 3. Analysis of HPV8-E2 binding to the M29 sequence element. (A) Nucleotide sequences of the E2 consensus recognition site, the HPV8-M29 motif,
and oligonucleotides M29E2, M29E2mut, and P2C. The mutated nucleotides in M29E2mut and P2C are highlighted in bold letters. The oligonucleotide P2C
contains the exchange CC3AA in the HPV8-E2-binding site P2 and has a higher affinity to E2 compared with the wild-type sequence (Stubenrauch et al.,
1994). (B) E2 is able to form DNA–protein complexes with the M29 element. Binding was analyzed by adding E2 protein to aliquots of 32P-labeled M29E2
or P2C oligonucleotides. For competition unlabeled oligonucleotides that represent individual E2-binding sites (M29E2, P2C) were added in 100-fold excess.
Unlabeled SP1 and M29E2mut oligonucleotides were used as nonspecific competitors. Control reaction mixtures received no protein.
282 B. Akgu¨l et al. / Virology 308 (2003) 279–290
p53 inhibits HPV8 DNA replication
Because of the fact that p53 binds to the M29 motif,
which is an essential element of the origin, we were inter-
ested to see whether p53 influences the DNA replication of
HPV8. Cotransfection of human p53 wt expression vector
pCp53wt suppressed the replication of the HPV8 replication
test plasmid p85 (Figs. 2A and 5). In contrast, cotransfection
with the expression vector pCp53175, encoding for a p53
mutant protein at amino acid 175, which is not able to bind
to DNA, did not inhibit replication (Fig. 5). We convinced
ourselves that p53 inhibition of replication is not due to
Fig. 4. In vitro translated p53 binds to the HPV8 M29 sequence element. (A) The M29 sequence (top) compared with the p53-binding site consensus sequence.
Comparison of the putative p53-binding site in the HPV8 sequence motif M29 with the p53 consensus binding site, consisting of two sequence decamers,
which are separated by 0–13 nucleotides. Bases in M29 matching the consensus sequence are underlined. (B) 32P-end-labeled double stranded oligonucle-
otides corresponding to the M29 sequence were incubated with in vitro translated p53 in the presence of the anti-p53 antibody pAb421. DNA–protein
complexes were separated by nondenaturing polyacrylamide gel electrophoresis. Where indicated, experiments were performed in the presence of the
unlabeled oligonucleotides M29com and p53c as specific and p53c as unspecific competitors. The positions of the p53-specific bands are indicated by
the arrow.
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pleiotropic, nonspecific effects following induction of apo-
ptosis. Flow cytometric analysis of annexin-labeled cells
gave no evidence of apoptosis up to 72 h post-transfection
of pCp53wt (data not shown).
Interaction between HPV8-E2 and p53
It has recently been demonstrated that E2 protein of the
high-risk genital HPV type 16 can directly bind p53 (Mas-
simi et al., 1999). In order to test if this might also be the
case for HPV8-E2 we expressed HPV8-E1 and -E2 as GST
fusion proteins in Escherichia coli (Enzenauer et al., 1998)
and investigated their ability to bind in vitro translated p53
by a series of GST pulldown assays. The results obtained
are shown in Fig. 6. It is clear that E2 retains a significant
portion of the input p53 protein, in contrast with no binding
to GST-E1 and the GST alone.
HPV8-E2 displaces p53 from its binding site within the
ori element
In view of the fact that the binding sites of E2 and p53
proteins completely overlap we asked if these two proteins
can bind simultaneously to their overlapping target se-
quences. To answer this question band-shift tests were per-
formed with constant concentrations of p53 and increasing
amounts of E2. As can be seen in Fig. 7, high concentrations
of E2 protein were able to displace p53 from its binding site.
There was no additional complex detected, indicating that
the proteins are not able to bind to the same oligonucleotide
and that no protein–protein interaction occurs between
DNA-bound E2 and p53. The displacement shows that
binding of p53 and E2 to their target sites within the ori
element is mutually exclusive.
p53 activates the E6 oncogene promoter of HPV8
Since the M29 motif represents a core element of the
HPV8 E6 promoter P175 (Pajunk et al., 1997) we analyzed
the functional relevance of the p53-M29 interaction for its
activity. To construct an E6 promoter-specific test plasmid,
the 3 part of the NCR (nt 10–558) was cloned into the
promoterless luciferase vector pALuc. The HPV8 fragment
chosen for this purpose encompasses the P175 cap site
(Stubenrauch et al., 1992) and contains a number of se-
quence elements conserved among most of the EV-specific
HPV types in their E6 proximal NCR parts (P4, CCAAC,
M29, A/T). Since P175 activity depends on a constitutive
enhancer element located in the 5 region of the NCR, we
inserted a dimer of the transcriptional enhancer element
M33/AP1 (Horn et al., 1993) in front of the promoter
fragment. The resulting reporter gene plasmid pNCR8-3-
Luc was cotransfected with an expression vector for wild-
type p53 into RTS3b cells. As shown in Fig. 8 E6 promoter
activity increased 2.5- 3-fold upon p53 overexpression. To
confirm that this enhancement was mediated by the p53
interaction with DNA, pNCR8-3-Luc was cotransfected
with an expression vector encoding mutated p53
(PCP53175), which is not able to bind to DNA (Nigro et al.,
1989). It can be seen that the (over)expression of p53175
protein had no noticeable effect on the promoter activity of
pNCR8-3-Luc. In order to confirm that the p53-binding site
is involved in p53-dependent P175 activation we mu-
tagenized plasmid pNCR8-3-Luc within the 5 decamer of
its p53 recognition site (pNCR8-3-Luc-p53mut) and tested
it in transient promoter assays upon cotransfection of the
wild-type p53-expressing vector. Data presented show that
the mutated p53-binding site disables its stimulating influ-
ence on the P175 promoter of HPV8. These results prove that
p53 acts as an activator of the E6 promoter by virtue of its
binding to the M29 element.
Cotransfection of p53 and E2 expression vectors led to a
sixfold activation of pNCR8-3-Luc compared with a two-
fold activation by E2 alone (data not shown). This suggests
that at relative concentrations of p53 and E2, which led to
inhibition of replication, p53 still activates the E6 promoter
of HPV8.
Fig. 6. p53 binds in vitro to HPV8-E2. Protein affinity chromatography of
GST, GST-E1, and GST-E2 with in vitro translated p53. GST fusion
proteins GST-E1 and GST-E2 or GST protein were immobilized on glu-
tathione Sepharose, incubated with in vitro translated p53, and washed as
described in Enzenauer et al. (1998). The bound p53 protein was separated
by SDS–polyacrylamide gel electrophoresis and detected by autoradiogra-
phy.
Fig. 5. Wild-type p53 suppresses HPV8 DNA replication. In this assay p53
expression vectors pCp53wt and pCp53175 were additionally transfected in
transient replication assays. Overexpression of p53wt inhibits HPV8 DNA
replication, whereas the p53 mutant 175, which is no longer able to bind to
DNA (Nigro et al., 1989) has no effect. Low-molecular-weight DNA was
isolated and linearized with BamHI. Half of each sample was then digested
with Dpnl ( or ). The preparations were finally analyzed by Southern
blot hybridization.
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Discussion
All eucaryotic ori sequences generally display the same
structural organization, typically consisting of an origin
recognition element, a DNA unwinding element, binding
sites for auxiliary transcription factors, and in many cases a
local A/T-rich segment (DePamphilis, 1993). The data
available so far argue that origins of HPVs also follow this
pattern. However, they have been raised primarily for a
subgroup of HPVs, infecting almost exlusively the mucosal
epithelia. In the course of this study we mapped and char-
acterized an ori element of the EV-associated HPV8, a
representative of the most ubiquitous group of skin-specific
HPVs.
It could be shown that the ori of HPV8 resides in the E6
proximal part of its NCR. The location of the HPV8 ori is
thus similar to that of other papillomaviruses analyzed in
this regard, which supports the postulated, highly conserved
functional architecture of their genomes. However, in con-
trast to other HPVs the NCRs in EV viruses are much more
compact and show a unique, group-specific sequence orga-
nization (Fuchs and Pfister, 1997).
The smallest NCR fragment necessary and sufficient to
fulfill the ori function in HPV8 consists of a 65-bp DNA
fragment containing two sequence elements, CCAAC and
M29, which are highly conserved exclusively among most
of the EV HPVs. Interestingly, the very same fragment
could also be shown to constitute an essential part of the E6
oncogene promoter (Horn et al., 1993; Pajunk et al., 1997).
This is reminiscent of the organization of the regulatory
Fig. 7. HPV8-E2 and p53 protein competitively bind to M29. EMSAs were performed with the M29com oligonucleotide, 4 l of in vitro translated p53
protein, and increasing amounts of purified HPV8-E2 protein.
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sequences of polyomaviruses, characterized by intermin-
gled sequence modules, serving both replication and tran-
scription.
The exact roles of the CCAAC and M29 motifs in DNA
replication have thus far not been clear. The sequence anal-
ysis of the CCAAC element, however, strongly suggests
that it may serve as a binding site for the essential HPV
replication factor E1. As shown below, an alignment of the
CCAAC sequence of HPV8 with the consensus binding site
for E1 proteins (O’Conner et al., 1995) displays only two
mismatches over a stretch of 20 bp: (E1 consensus site)
TWNTWATWNHWWWYWAYAAT and (CCAAC se-
quence) TTGTTATTGCCAACAACCAT.
It could be demonstrated here that a part of the second ori
element of HPV8, M29, adopts in its turn the function of an
E2-BS. The newly identified E2 target sequence 5-
ATCGN4CGAT-3 (P5) differs from the consensus of an
E2-BS (5-ACCN6GG/TT-3) originally defined for the bo-
vine papillomavirus 1 (Li et al., 1989) and from a novel
E2-BS 5-ACACN5GGT-3, recently reported to be active
in supporting HPV transcription and replication (Newhouse
and Silverstein, 2001). P5 seems to represent an E2-BS of
relatively high affinity, comparable at least to that of P2C
(Stubenrauch and Pfister, 1994). Taken together these data
argue that the actually active E2-BSs may also display a
considerable degree of sequence variation in their symmet-
ric flanks, thus far regarded as conserved parts of the E2-
binding palindrome. Interestingly, the M29 E2-BS cannot
be recognized by the BPV1-E2 protein (G. Steger, personal
communication).
Although the minimal ori element of HPV8 as defined by
assays with p88 is characterized by a rather high content of
A and T residues (60%), there is no clearly recognizable
continuous stretch of these nucleotides. Interesting in this
regard is the fact that the 34-bp A/T sequence located 3
from the ori of HPV8 and characteristic of most of the
EV-associated viruses turned out to be dispensable for its
transient in vitro replication ability.
Our analysis of the M29 sequence furthermore revealed
the presence of an element very closely resembling a puta-
tive binding site of the tumor suppressor protein p53.
p53-BS consists of two copies of the 10-bp motif 5-PuPu-
PuC(A/T)(T/A)GPyPyPy-3 separated by 0- to 13-bp spacer
(El-Deiry et al., 1992). Both decamers within M29 differ
from this consensus in containing pyrimidine bases in its
conserved purine regions, as well as by the spacer element
of 14 bp (Fig. 4A). Nevertheless, we demonstrated that this
sequence can indeed act as a functional p53-BS.
Having thus identified an authentic p53-binding site
within the ori element, we asked if and how p53 may
influence the replication of HPV8. At least in transient in
vitro assays, p53 completely inhibited HPV8 DNA replica-
tion, while in contrast, the DNA-binding-defective H175
mutant of p53 displayed no effect at all. These findings
argue that physical interactions between p53 and the ori
sequence may represent one of the mechanisms controlling
the course of skin infection by HPV8. Moreover, we de-
tected formation of a complex of p53 and E2 in the absence
of DNA. The latter is in line with previous data raised for
HPV16-E2 (Massimi et al., 1999). We suggest that the
Fig. 8. p53 activates the E6 oncogene promoter of HPV8. The structure of the HPV8 NCR fragment cloned into pALucis is shown on top. Different graphic
symbols mark the localization of characteristic sequence motifs (a dimer of M33/AP1, P4, CCAAC, M29, A/T). Luciferase activity in extracts from RTS3b
cells transfected with pALucNCR8-3-Luc and pALucNCR8-3-Lucp53mut and p53 expression vectors (wild-type and mutant 175). The pCMV--Gal
plasmid was cotransfected as an internal control for transfection efficiency. Promoter activities are presented as luciferase/-galactosidase activity ratios.
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observed displacement of p53 from its BS by E2 and per-
haps also the DNA-independent, direct p53–E2 interactions
can be instrumental in replicational repression by p53. The
same inhibitory effect of p53 on amplificational replication
has previously been reported in vitro for bovine papilloma-
virus 1 and HPV11 in CHO cells by Lepik et al. (1998).
However, in this case the authors concluded that while the
DNA-binding domain is essential for the repression activity
of p53, there is no need for a p53 response element within
the ori. Irrespective of this discrepancy, it is tempting to
speculate that p53–E2 interactions may play a general role
in regulating papillomavirus replication.
The results presented show that besides its influence on
the function of the ori element, p53 may also affect the
activity of the overlapping E6 oncogene promoter P175 (Pa-
junk et al., 1997) depending on the binding of p53 to its
cognate sequences. Surprisingly, however, the effects of
p53 upon HPV8 replication and transcription turned out to
be opposite, since overexpression of p53 resulted in activa-
tion of the P175 activity. Stimulation of P175 activity could
be observed in the p53-negative RTS3b cell line used
throughout this study as well as in normal primary keratin-
ocytes isolated from breast skin (data not shown).
Taken together, these observations strongly suggest that
E2 and p53 are involved in the control of the balance
between viral DNA replication and oncogene expression in
the course of skin infection with EV HPVs. Unfortunately,
there is to date only little information concerning the pat-
terns of expression of both these factors in normal and
dysplastic human skin epithelium. The p53 protein has been
detected in the cytoplasm of the basal cell layer in normal
skin and in psoriatic lesions (Helander et al., 1993). In
contrast, squamous cell carcinomas of the skin revealed
diminuished p53 expression, confined in a subset of cases to
the cell nucleus. In regard to cell proliferation it is interest-
ing to note that p53 was reported to accumulate in the
cytoplasm during the G1 phase of the cell cycle and to
relocate to the nucleus at the beginning of the S phase
(Shaulsky et al., 1990). In the case of EV lesions immuno-
histochemical p53 positivity could be detected in almost all
specimens studied (Pizarro et al., 1995). A study of Pad-
lewska et al. (2001) revealed nuclear staining mostly con-
fined to basal cells. On the other hand, the E2 transcription
in HPV5-induced benign EV skin lesions could be shown
by in situ hybridization to occur predominantly in the cen-
tral layers of the stratified epithelium (Haller et al., 1995).
Combining these data with our results one can envisage
a scenario in which the gradients of p53 and E2 expression
in differentiating skin keratinocytes decide on preference
between virus DNA replication and transcription of the
HPV8 E6 oncogene. This would fit the limited (mainte-
nance) replication of HPV DNA in basal/suprabasal strata
and the productive replication in the middle and upper parts
of the epithelium. The demonstrated impact of p53 on HPV
replication may also be relevant to the establishment of
latent infections, typical for EV viruses.
Materials and methods
Oligonucleotides
Oligonucleotides used to generate subfragments of the
HPV8 NCR by PCR consisted of 12–14 nt, with their 5
ends at positions given in Fig. 2A.
Band-shift experiments were performed with the double
stranded oligonucleotides P2C (nt 7486–7516, AAC-
CGACCGCAAACGGTACATAAAGGTGAGT), with a
high-affinity E2 recognition site as described in Stuben-
rauch and Pfister (1994); M29com (nt 79–118, CTATAG-
CATGTTTTTGCCTGTATCGTTTTCGATCACACC);
M29E2 (nt 94–117, GCCTGTATCGTTTTCGATCA-
CACC); M29E2mut (nt 94–117, GCCTGTCTGGTTTTC-
GATCACACC); SP1, with a bona fide SP1-binding site
(GATCTAAACCCCGCCCAGCG); p53control oligo-
nucleotide (TACAGAACATGTCTAAGCATGCTGGGG);
and p53-control oligonucleotide (TACAGAATCGCTCTA-
AGTCGCCTGGGG), all purchased from Santa Cruz Bio-
technology, Inc. (Santa Cruz, CA, USA). Nucleotide num-
bering of the HPV8 sequence is according to Fuchs et al.
(1986).
Plasmids
Expression vectors
The E1 expression vector pCE1 was generated by inser-
tion of the HPV8 PvuII fragment (nt 828–2937) into the
BglII site of the vector pCB6, downstream of the CMV
immediate-early promoter. The HPV8-E2 expression vector
pCE2 was constructed by inserting the whole E2 open
reading frame of HPV8 (nt 2682–4222) into pCB6 (Stuben-
rauch and Pfister, 1994).
The eucaryotic expression vector pCp53wt contains the
wild-type human p53 cDNA (Nigro et al., 1989), whereas
its mutant form pCp53175 encodes for an amino acid ex-
change from arginine to histidine at position 175 and is no
longer able to bind DNA. p53 expression vectors pSp53wt
for in vitro translation and pGEX-2Tp53 for the expression
of GST-fused p53 were as described elsewhere (Zimmer-
mann et al., 1999). The GST fusion vectors for HPV8-E1
and E2 are described in Enzenauer et al. (1998).
Replication test plasmids for HPV8
The plasmids p81 (nt 7626–188), p82 (nt 7626–118),
p83 (nt 7626–51), p84 (nt 7626–81), p85 (nt 13–118), and
p86 (nt 13–75) were generated by PCR amplification of the
HPV8 fragments, which were then cloned into the SmaI site
of pUC8. In p87 the CCAAC element (nt 56–75) was
replaced by a linker sequence (CATGGAGCTCTATAG).
p88 (nt 34–115) was generated by ligation of a dou-
blestranded synthetic oligonucleotide into the SmaI site of
pUC18. To construct P01234, the Eco47III-XhoI restriction
fragment of the vector P34 (Stubenrauch and Pfister, 1994)
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was inserted into P012 (Stubenrauch and Pfister, 1994), in
which the same sequence was previously deleted.
Luciferase gene reporter plasmids
The HPV8 E6 promoter plasmid pNCR8-3-Luc was
generated by cloning of an HPV8 PCR amplicate (nt 10–
558) between the HindIII–KpnI sites and a dimer of a
double stranded oligonucleotide corresponding to the HPV8
M33/AP1 enhancer (nt 7422–7474, Horn et al., 1993) into
the HindIII site of pALuc.
Site-directed mutagenesis
In order to introduce nucleotide exchanges into HPV8
sequences, site-directed mutagenesis was performed by us-
ing the QuikChange site-directed mutagenesis kit (Strat-
agene). To mutate the E2- and p53-binding motives within
the ori element of HPV8 the sense/antisense oligonucleotide
pairs p88E2mutA 5-GCATGTTTTTGCCTGTCTGGTTT-
TCGATCACACC-3/p88E2mutB 5-GGTGTGATCGAA-
AACCAGACAGGCAAAAACATGC-3 and pNCR8-3-
Luc-mutA 5-CCATCGTCTATAGTCGCTTTTTGCCTG-
TATCG-3/pNCR8-3-Luc-mutB 5-CGATACAGGCAA-
AAAGCGACTATAGACGATGG-3 were used. After ob-
taining positive clones, the constructs were sequenced to
confirm the mutated nucleotides in the context of the HPV8
sequences.
Cell culture
The spontaneously immortalized human skin keratino-
cyte cell line RTS3b (Purdie et al., 1993), which contains no
papillomavirus DNA, was maintained in F12–DMEM (1:4)
supplemented with hydrocortisone (0.4 mg/ml), 1010 M
cholera toxin, transferin (5 mg/ml), 2  1011 M triiodo-
thyronin, 1.8  104 M adenin, insulin (5 mg/ml), epider-
mal growth factor (10 ng/ml), 1% penicillin–streptomycin,
and 10% fetal calf serum.
Transient replication assay
RTS3b cells were transfected with plasmid DNA with
Fugene (Roche, Mannheim) according to the manufactur-
er’s protocol. Transient replication assays were done with 6
 106 cells in 100-mm plates and 2 g of the expression
vectors pCE1, pCE2, pCp53wt, and pCp53175 and 3 g of
ori plasmids; 72 h after transfection, low-molecular-weight
DNA was isolated according to the protocol established by
Ustav and Stenlund (1991). The plasmid DNA was linear-
ized with BamHI as a single cutter. To distinguish between
replicated and unreplicated DNA, half of each sample was
additionally treated with DpnI to remove the unreplicated,
methylated input DNA. The DNA samples were analyzed
by electrophoresis in 0.8% agarose gels followed by South-
ern blot hybridization. The DNA was transferred to Hybond
N membrane (Amersham) and hybridized to a 32P-labeled
pNCR8-CAT probe generated by using the random primer
labeling kit (Gibco). Blots were subjected to autoradiogra-
phy at 70°C with intensifying screens.
Transient gene expression assay
Twenty-four hours prior to transfection 2  105 RTS3b
cells were plated into 6-well culture dishes. Each plate
received equal amounts of DNA composed of 500 ng of
Luciferase gene reporter plasmid, 200 ng of the expression
vector pCMV--Gal, and up to 200 ng of the p53 expression
vectors pCp53wt or pCp53175. The total amount of plasmid
DNA was kept constant in cotransfection by the addition of
plasmid pCMV1. Cells were harvested 24 h after transfec-
tion in PBS, resuspended in 100 mM potassium phosphate,
pH. 7.8, containing 1 mM dithiothreitol, and lysed by 4
freeze–thaw cycles. Luciferase activity was quantified as
described by DeWet et al. (1987). The promoter activity
was expressed as ratio of luciferase to -Gal activities.
Expression and purification of HPV8 E2 protein from
insect cells
High Five insect cells (Trichoplusia ni 5B1-4, Invitro-
gen) were cultivated in Express Five serum-free medium
(Gibco) at 27°C. The infection of cells was performed as
described by Stubenrauch and Pfister (1994); 72 h postin-
fection cells were resuspended in a total volume of 10 ml of
PBS containing 1 mM phenylmethylsulfonyl fluoride
(PMSF) and protease inhibitor cocktail (Roche, Mannheim).
The suspension was frozen in liquid Nitrogene and then
thawed at 42°C three times to lyse the cells. The crude
lysate was centrifugated at 15,000  g and the supernatant
was applied to a 5-ml HiTrap heparin–Sepharose column
(Pharmacia). HPV8 E2 protein was eluted with 0.6 M KCl.
GST fusion protein purification and in vitro binding
assays
GST fusion protein expression and purification was done
as described previously (Enzenauer et al., 1998). In vitro
translations were performed using the TNT-coupled reticu-
locyte lysate system (Promega) as instructed by the manu-
facturer. For p53 EMSAs the p53 protein was in vitro
synthesized with the modification that no radiolabeled
amino acids were used.
Electromobility shift assay (EMSA)
32P-end-labeled oligonucleotides (250 pg) were incu-
bated with HPV8-E2 protein in a total volume of 20 ml of
binding buffer (10 mM HEPES, pH 7.9, 50 mM KCl, 2 mM
MgCl2, 0.25 mM dithiothreitol, 4 mM spermidine, 5 mg/ml
of bovine serum albumin, 5% glycerol (v/v) and 1 mg
poly(dl-dC)poly(dl-dC)). For competition experiments, the
reactions were supplemented with different amounts of ho-
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mologous and heterologous unlabeled oligonucleotides. Af-
ter 20 min at room temperature, the samples were electro-
phoresed in 5% native polyacrylamide gels.
For each p53 EMSA test, 4 l of p53-primed reticulocyte
lysate was diluted in 20 l of DNA-binding buffer (20 mM
Tris–HCl, pH 7.5, 100 mM NaCl, 0.1% NP-40 (v/v), 10%
glycerol (v/v), 5 mM dithiothreitol) and 50 ng of salmon
sperm DNA as a non specific competitor. Where required,
reactions were performed in the presence of unlabeled com-
petitor oligonucleotides. Reactions were incubated for 10
min at ambient temperature with the labeled oligonucleo-
tides, followed by the addition of 1 ml of anti-p53 mono-
clonal antibody pAb421 (Hupp et al., 1992). The samples
were incubated for a further 30 min and finally subjected to
4% nondenaturing polyacrylamide gel electrophoresis. The
gels were vacuum dried and exposed to X-ray film over-
night at 80°C.
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